Mephedrone (4-MMC)
Mephedrone (4-MMC) is a synthetic cathinone stimulant chemically related to the khat plant's active compound. It produces MDMA- and cocaine-like effects — euphoria, energy, and sociability — but carries serious risks including sympathomimetic toxicity and a strong urge to redose.
Overview
Mephedrone, also called 4-methylmethcathinone or 4-MMC, is a synthetic stimulant of the cathinone class. Cathinones are chemically related to the natural stimulant found in the khat plant (Catha edulis) of East Africa; mephedrone is a laboratory-made member of this family and a beta-keto analogue of an amphetamine. It first appeared on the recreational drug market around 2007-2009, sold online and in "head shops" as a legal alternative to MDMA (ecstasy) and cocaine, and became widely used before being banned. It usually comes as a white or off-white powder or in capsules, and people typically swallow it, wrap it in paper and swallow it ("bombing"), or snort it; injecting also occurs and is especially dangerous. Common street names include drone, M-CAT, meow meow, and bubble.
Source: EMCDDA/Europol Joint Report; peer-reviewed pharmacology literature
Chemistry & mechanism of action
Mephedrone works by acting on the brain's monoamine systems — the same broad targets as MDMA, amphetamines, and cocaine. It is a non-selective monoamine releaser and reuptake inhibitor, meaning it both triggers release of and blocks the reabsorption of dopamine, norepinephrine, and serotonin. Its balance between dopamine and serotonin effects (a dopamine-to-serotonin transporter ratio of roughly 1.4) sits between that of cocaine and MDMA, which is why users often describe it as a mixed "MDMA-cocaine-like" drug — part euphoric stimulant, part empathogen. In this respect it acts as a releaser, similar to methylone, and differently from MDPV, which mainly blocks reuptake without triggering release. Its effects come on quickly and are relatively short-lived, which contributes to the strong tendency to redose.
Source: peer-reviewed pharmacology literature
Effects
People report that mephedrone produces euphoria, increased energy and alertness, talkativeness, feelings of warmth and closeness to others, and heightened sociability — an effect profile overlapping ecstasy and cocaine. Onset is rapid and the main effects are short-lasting, often less than an hour, which drives a strong and well-documented urge to take repeated doses in a session. Common unwanted effects include jaw clenching, teeth grinding, sweating, dilated pupils, raised heart rate and blood pressure, agitation, and difficulty sleeping.
Source: peer-reviewed pharmacology literature; EMCDDA/Europol Joint Report
Risks & harms
Mephedrone's central risks come from over-stimulation of the cardiovascular and nervous systems (sympathomimetic toxicity): rapid or irregular heartbeat, chest pain, dangerously high blood pressure, overheating, agitation, and, in severe cases, seizures. Because effects are short and intense, compulsive redosing is common and raises the total dose and the strain on the body. At least 90 deaths have been documented in which mephedrone alone or combined with other substances was implicated, and the risk climbs sharply when it is mixed with other stimulants, alcohol, or depressants, or when it is injected. Repeated heavy use is associated with anxiety, paranoia, low mood, and dependence. As with other cathinones sold as powders, actual purity and contents vary and a product sold as one cathinone may be another.
Source: peer-reviewed pharmacology literature; EMCDDA/Europol Joint Report
Legal status (US)
Mephedrone is a controlled substance in most countries. It was banned across the European Union in 2010 following an EMCDDA-Europol risk assessment, and it was placed under federal control in the United States in 2012, where cathinones such as mephedrone are Schedule I substances. Despite these bans it has remained in circulation. Legal status varies by country and can change; local law is what applies to you.
Source: EMCDDA/Europol Joint Report; US federal law
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
After MDMA, overheating and over-hydration are both dangerous: cool down, and sip to thirst rather than gulping water (forcing plain water can drop your blood sodium dangerously).
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 45266826PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- 2-(methylamino)-1-(4-methylphenyl)propan-1-onePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C11H15NOPubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CC1=CC=C(C=C1)C(=O)C(C)NCPubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- YELGFTGWJGBAQU-UHFFFAOYSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- 4-mmc, meow meow, mephedrone, 4-methylmethcathinone, Meow meow, 4-MMC, M-CAT, 4-methylephedrone, bk-4-methylmethamphetamine, MMCAT compound, 4-MMC compound, BubblesPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA ↗ · retrieved 2026-06-18
Effects
- Effects
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Risks
- Risks
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Interactions
- Interactions
- Unknown — pending review
Dosage
Pending medical reviewer
